<DOC>
	<DOCNO>NCT01073189</DOCNO>
	<brief_summary>Randomized prospective trial patient diuretic unresponsive acute kidney injury patient receive standard supportive therapy diuretic versus intra-renal delivery vasodilator fenoldopam mesylate . Patients rise creatinine fail respond bolus diuretic treat prolonged course diuretic undergo placement catheter within renal artery allow infusion fenoldopam mesylate . The rational early delivery high dose vasodilator may reverse decline renal function patient severe acute kidney injury .</brief_summary>
	<brief_title>Intra-Renal Therapy Diuretic Unresponsive Acute Kidney Injury</brief_title>
	<detailed_description>Acute kidney injury ( AKI ) common complication hospitalize patient associate increased morbidity mortality 1 . The pathogenesis AKI complex , time dependent process involve multiple variable include significant reduction renal blood flow ( RBF ) , interstitial infiltration activate neutrophils obstruction tubule lumens necrotic debris . In human study animal model , change RBF early event reduction RBF 40-50 % . The mechanisms blood flow fall onset AKI unknown , release multiple vasoconstrictor couple loss autoregulation lead prolonged reduction RBF 2 . The loss ability vasodilate autoregulate renal blood flow increase sensitivity additional ischemic nephrotoxic insult . Because reduction RBF contribute progression AKI , clinical maneuver restore blood flow ischemic kidney offer potential significantly reduce patient mortality3 . Consequently , numerous vasodilator investigate determine whether restore blood flow clinically reduce incidence dialysis dependent AKI . Some agent include fenoldopam mesylate show encouraging result specific sub-populations , benefit agent include atrial natriuretic peptide offset development systemic hypotension . The hypotenisve effect agent significant limitation effort restore blood flow ischemic kidney . Moreover , potential additive hypotension side effect impede creation `` cocktail '' multiple agent could ability simultaneously activate numerous different protective pathway . Recent work use FlowMedica Benephit catheter show intra-renal delivery vasodilator allow target organ protection without development systemic side-effects . Moreover , intra-renal delivery fenoldopam mesylate vasodilator allow supra-pharmacologic dos lead prolonged beneficial effect RBF GFR . We hypothesize intra-renal delivery fenoldopam mesylate patient early AKI significantly reduce number patient require renal replacement therapy . To investigate hypothesis , propose study patient `` diuretic-resistant '' AKI randomize patient supportive care intermittent diuretic versus 24 hour intra-renal infusion fenoldopam mesylate combination intermittent diuretic therapy . The trial randomize prospective , open-labeled study 35 patient early AKI define 1.0 mg/dl rise serum creatinine baseline and/or two consecutive hour urine output le 20 mls/hr . The primary endpoint study peak serum creatinine day # 4 number patient require renal replacement therapy die within 8 day onset AKI . Additional data collect safety implementation complication associate 24 hour infusion fenoldopam use Angiodynamics Benephit catheter</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Fenoldopam</mesh_term>
	<criteria>1 . Any patient age 18 1.0 mg/dl rise serum Cr within 48 hour fall urine output le 20 mls/min X 2 consecutive hour . AND one two follow Options 2 . Failure double urine output within two hour 1.5 mg/kg bolus Furosemide OR 3 . Failure maintain 50 % increase urine output 4 consecutive hour follow single 1.5 mg/kg bolus furosemide WITH MD perform Urinalysis document presence 3 `` muddy brown cast '' per low power field ( LPF ) presence `` free renal tubular cell '' 1 . Patients APACHE score great 25 ( felt principle investigator survive 24 hour ) 2 . Patients MAP &lt; 65 two vasopressor patient require 3 presser agent ( epinephrine , + epinephrine vasopressin ) maintain MAP 65 mm Hg . 3 . Patients receive acute chronic peritoneal hemodialysis current hospitalization 4 . Patients receive dopamine fenoldopam infusion within previous 24 hour 5 . Patients require hemodynamic support intraaortic balloon pump 6 . Patients know HIV seropositivity 7 . Pregnant lactate woman 8 . Patients actively receive NSAIDS COX2 antagonists 9 . Patients history uncontrolled cardiac arrhythmia 10 . Patients give informed consent . 11 . Patients know hypersensitivity fenoldopam mesylate 12 . Patients know bleed diathesis 13 . Patients know blockage one renal artery 14 . Patients know condition would increase likelihood vascular perforation , trauma , dissection Marfan 's syndrome , cystic medial necrosis , abdominal thoracoabdominal aortic dissection , mycotic aneurysm , abdominal aneurysm , thoracoabdominal aneurysm , renal artery aneurysm , thoracic aneurysm involve visceral region aorta , severe calcification area renal artery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Acute kidney injury</keyword>
	<keyword>Fenoldopam mesylate</keyword>
	<keyword>Benephit catheter</keyword>
</DOC>